✦ LIBER ✦

Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer

✍ Scribed by Patricia J. Hollen; Richard J. Gralla; Cynthia N. Rittenberg

Publisher: Springer-Verlag
Year: 2004
Tongue: English
Weight: 128 KB
Volume: 12
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-004-0639-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Shenfu injection plus vinorelbine for el

Shenfu injection plus vinorelbine for elderly patients with non-small cell lung cancer in promoting the quality of life: a randomized controlled clinical trial

✍ Yan Hu; Anji Hou; Hongwei Zhang; Wei Zhou; Xiaoyan Shen; Yanli Huang; Li Zhou 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 143 KB

Estimating the quality of life in a clin

Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index—cancer

✍ Patricia A. Ganz; Charles M. Haskell; Robert A. Figlin; Nancy La Soto; Jessie Si 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 697 KB

## FOR THE UCLA SOLID TUMOR STUDY GROUP11 Serial assessments of Karnofsky performance status (KPS) and of the Functional Living Index-Cancer (FLIC) have been used to estimate the quality of life (QOL) of patients in a prospective, randomized trial of supportive care versus supportive care given wi

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati